Home › Bell Radar › RTSN

RTSNRetension Pharmaceuticals

US ExchangeHealth Care2026-10-09

Clinical-stage biopharma developing oral PDE5 inhibitor RTN-001 for hypertension and cardiovascular diseases.

$12IPO price
$46MRaised
$10.53Day-1 close
-12.25%Day-1 return
Clinical-stage biopharma developing oral PDE5 inhibitor RTN-001 for hypertension and cardiovascular diseases.
Company description (source: StockAnalysis)

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.

生物医药临床阶段心血管
51CFO read: Requires CFO with clinical-stage biotech finance: FDA-regulated cap planning, trial cost governance, and IPO-scale fundraising execution.
Management details per the SEC prospectus.
Company profile SEC prospectus
Does your company need this kind of CFO?

51CFO is an investment banking team focused on the US market: US IPOs, reverse mergers, shell deals, SPAC and De-SPAC, SEC filings and post-listing follow-ons, run by one team from structure to opening bell. Free 30-minute listing-route diagnosis, answered within 24 hours.

Talk to us